hotspot -WSS

hotspot

author：comprehensive 2025-09-28 23:48:46 - browse：59

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Mayo Clinic plans $5B tech

entertainment

WSS

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

U.K. Biobank has 500,000 peoples' genome sequences available

Cigna, Humana reportedly in talks to merge

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Large hospital system sues Multiplan for low

Pediatric cancer treatments threatened by a new FDA policy

entertainment

hotspot

knowledge

In age of alternative facts, a scholarly course on calling out crap

TB outbreak tied to bone grafts underscores testing shortcomings

Medicare details structure of new drug price negotiation program

After John Oliver segment, STAT readers share their opioid

What does generative AI mean for health care? We asked experts

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Sports medicine is finally prioritizing gender equality

CDC overhauls leadership of center that led response to Covid

Affirmative action in medical school literally saved lives

Takeda, Janssen join wearable maker to measure scratching

entertainment

How to pay for weight loss drugs and save Medicare

UnitedHealth’s Optum accused of antitrust violations in California

Rep. Raul Ruiz on the physician shortage and more

Pharma budget tightening trickles down to Doximity

FDA investigates CAR

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

entertainment

hotspot

focus

entertainment